Evolent Health, Inc. (NYSE:EVH) Stock Position Cut by WoodTrust Financial Corp

WoodTrust Financial Corp lessened its stake in Evolent Health, Inc. (NYSE:EVH) by 7.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,650 shares of the technology company’s stock after selling 3,500 shares during the period. WoodTrust Financial Corp’s holdings in Evolent Health were worth $1,206,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Quarry LP acquired a new stake in Evolent Health in the 2nd quarter valued at about $32,000. GAMMA Investing LLC lifted its holdings in Evolent Health by 5,365.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after acquiring an additional 1,556 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Evolent Health in the 1st quarter valued at about $46,000. Canada Pension Plan Investment Board acquired a new stake in Evolent Health in the 2nd quarter valued at about $61,000. Finally, Quest Partners LLC acquired a new stake in Evolent Health in the 2nd quarter valued at about $87,000.

Insider Buying and Selling

In related news, President Daniel Joseph Mccarthy sold 23,693 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total value of $731,876.77. Following the transaction, the president now owns 198,809 shares in the company, valued at approximately $6,141,210.01. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Evolent Health news, President Daniel Joseph Mccarthy sold 23,693 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total transaction of $731,876.77. Following the transaction, the president now owns 198,809 shares in the company, valued at $6,141,210.01. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Jonathan Weinberg sold 42,140 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $31.20, for a total value of $1,314,768.00. Following the transaction, the general counsel now owns 167,027 shares in the company, valued at approximately $5,211,242.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 307,291 shares of company stock worth $9,290,385. Insiders own 1.60% of the company’s stock.

Evolent Health Stock Performance

Shares of EVH opened at $24.78 on Thursday. The business’s 50-day moving average is $27.35 and its 200-day moving average is $24.98. Evolent Health, Inc. has a fifty-two week low of $17.98 and a fifty-two week high of $35.00. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.57.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, August 8th. The technology company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.09. Evolent Health had a positive return on equity of 8.47% and a negative net margin of 3.16%. The firm had revenue of $647.10 million for the quarter, compared to the consensus estimate of $636.46 million. During the same quarter in the prior year, the company posted $0.06 earnings per share. The firm’s revenue was up 37.9% on a year-over-year basis. On average, analysts anticipate that Evolent Health, Inc. will post 0.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EVH has been the subject of a number of research analyst reports. Citigroup cut their price target on shares of Evolent Health from $35.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. Truist Financial reaffirmed a “buy” rating and set a $33.00 price objective on shares of Evolent Health in a research note on Tuesday, August 27th. Stephens reaffirmed an “overweight” rating and set a $42.00 price objective on shares of Evolent Health in a research note on Tuesday, July 30th. JPMorgan Chase & Co. upped their price objective on shares of Evolent Health from $36.00 to $45.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Finally, KeyCorp began coverage on shares of Evolent Health in a research note on Friday, October 11th. They set an “overweight” rating and a $35.00 price objective for the company. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $38.60.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.